View attachment 585481
Actually Americans are essentially subsidizing the rest of the world’s medical research by paying out really high prices. 17.8% out of $20.5T, that's around $3.7T and
it's almost half of the world's healthcare spending ($7.7T), thanks to their fragmented market which increases prices. No country comes near to the US healthcare market, even though the US makes up only 25% of the world's GDP and around 5% of the world's population.
For drugs, they have very high research costs (fixed costs) and low marginal cost to produce. It takes a lot of money, time, effort to come up with new drugs, and even so it may not get the approval. But once it's approved, it's actually quite cheap to produce.
The first drug pill costs a billion dollars to produce, and the second pill onward costs a dollar. So what is the cost on average for producing 2 pills? 3 pills? 1 million pills? 1 billion pills?
As the US makes up almost half of the world's market, they shoulder most of the medical R&D costs in the world. Many of US pharmaceutical companies may then venture overseas, but really their main market is the US.
If the US bulk buys and brings down prices (which for ethical reasons I think they should), it's good for Americans but the global healthcare industry is going to take a beating. This means lesser profits and thus lesser future R&D capital and monetary incentives to innovate, and unless the rest of the world is willing to pay more for healthcare, medical innovations
may slow down in the future.
So it's a dilemma. Cheaper prices now (for Americans) or more medical innovations, which is better?
https://www.vox.com/platform/amp/sc...0/12945756/prescription-drug-prices-explained
One thing for sure, an expanding global economic pie is great for everyone, even if it's other countries which are growing. It's a globalized world, and other countries' growing purchasing power can bring down fixed costs such as R&D, not just for healthcare but for many other areas as well.
And for that, it's good that China with more a billion people is integrating into the global pharmaceutical markets which will bring down fixed costs and benefit everyone, including millions of Americans and Chinese. It's a win-win, and we should be gracious and wish them well.